Nektar Therapeutics
NKTR
194 hedge funds and large institutions have $2.28B invested in Nektar Therapeutics in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 76 increasing their positions, 66 reducing their positions, and 12 closing their positions.
142% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 12
19% more capital invested
Capital invested by funds: $1.91B → $2.28B (+$367M)
15% more repeat investments, than reductions
Existing positions increased: 76 | Existing positions reduced: 66
10% more funds holding
Funds holding: 177 → 194 (+17)
23% less call options, than puts
Call options by funds: $4.47M | Put options by funds: $5.77M
80% less funds holding in top 10
Funds holding in top 10: 5 → 1 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Westfield Capital Management
Boston,
Massachusetts
|
+$24.9M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$16.8M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.9M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$12.9M |
| 5 |
Two Sigma Investments
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$28.8M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$18M |
| 3 |
O
OppenheimerFunds
New York
|
-$17.2M |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$14.3M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$13.6M |
NKTR Hedge Fund Activity: Q3 2016 in Review
194 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2016, worth a combined $2.28B — up 19% from $1.91B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new NKTR positions and 12 closed out — a net gain of 17 holders — while 76 added to existing stakes and 66 trimmed.
The largest buyer was Westfield Capital Management, adding an estimated $24.9M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $28.8M sold.
- 194 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2016, up from 177 in Q2 2016.
- Funds reported $2.28B of Nektar Therapeutics stock for Q3 2016, up 19% quarter-over-quarter.
- 29 funds opened new Nektar Therapeutics positions in Q3 2016 and 12 closed out, a net change of +17 holders.
- The largest Nektar Therapeutics buyer in Q3 2016 was Westfield Capital Management, an estimated $24.9M added.
- The largest Nektar Therapeutics seller in Q3 2016 was Cormorant Asset Management, an estimated $28.8M sold.
Based on aggregated 13F filings for Q3 2016.